SB

Suman Bathla

Active Director Director DIN 10132517
DIN 10132517 First appointment Apr 2023 Primary industry Paper
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2023
Shareholding value •••• Premium profile

About Suman Bathla

Data last updated:

Suman Bathla is a Director at Ranvet Pharmaceuticals Private Limited (since 2023). The company operates in Paper. Ranvet Pharmaceuticals Private Limited reported revenue of ₹11.8 Lakh (FY 2025).

DIN 10132517
Primary Designation Director
Industry Paper
First Appointment 25 Apr 2023
Oldest Company Age 3 yrs
Largest company Ranvet Pharmaceuticals Private Limited · ₹11.8 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director25 Apr 20232023₹11.8 Lakh (FY 2025)Active

Board colleagues of Suman Bathla

Directorship timeline

Open interactive timeline →
Ranvet Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Suman Bathla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suman Bathla

Suman Bathla currently holds 1 directorship: Ranvet Pharmaceuticals Private Limited (Director, since 25 Apr 2023, revenue ₹11.8 Lakh (FY 2025)).

Suman Bathla was first appointed on 25 Apr 2023 as Director at Ranvet Pharmaceuticals Private Limited.

The current boards of Suman Bathla's companies include Hardik Bathla (Ranvet Pharmaceuticals Private Limited), Ravindra Kumar (Ranvet Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available